IMPORTANCE: Rising rates of obesity and youth-onset type 2 diabetes (YT2D) in children and adolescents have increased GLP-1 receptor agonist (GLP-1 RA) use, raising concerns about potential effects on suicidal ideation/behaviors (SI/SB), depression, and anxiety.
OBJECTIVE: To assess associations between GLP-1 RA use for obesity or YT2D and risk of SI/SB, depression, and anxiety in children and adolescents.
SETTING: OneFlorida+ EHR from January 1, 2020, to January 31, 2024.
DESIGN: Retrospective cohort study using prevalent-new user design, target trial emulation framework, and sIPTW for confounding control.
PARTICIPANTS: Children and adolescents with obesity or YT2D who were ≥6 and <18 years were included with no history of the respective outcomes.
EXPOSURE: New GLP-1 RA users vs. Prevalent metformin users.
OUTCOMES: SI/SB, anxiety, and depression. Weighted Cox proportional hazards models were used to assess the risk of outcomes. Risk differences (RD) and hazard ratios (HR) are presented with 95% CI. RDs are per 1,000 person-years.
RESULTS: The study included 2,010, 1,774, and 1,764 patients for SI/SB, depression, and anxiety, respectively. The mean age was ∼14.2 years, ∼61% were female, with up to 4 years of follow-up, across cohorts. Compared to prevalent metformin users, GLP-1 RA users had lower incidence and risk of SI/SB (RD: -10.45, -14.54 to -6.36; HR: 0.11, 0.02 to 0.86) and depression (RD: -25.64, -34.90 to -16.39; HR: 0.37, 0.17 to 0.78). There was no difference in anxiety risk between the two groups (RD: 5.95, -7.10 to 19.01; HR: 1.13, 0.69 to 1.84).
CONCLUSIONS: GLP-1 RA use may reduce the risks of SI/SB and depression among children and adolescents with obesity or YT2D; no association was found with anxiety. Long-term surveillance is needed.
KEY POINTS: Are GLP-1 receptor agonists (GLP-1 RAs) for the indication of obesity or youth-onset type 2 diabetes (YT2D) associated with the risk of mental health outcomes in children and adolescents?In this retrospective cohort study, including 2,116 children and adolescents with obesity or T2D, GLP-1 RA use was associated with a significantly lower risk of suicidal ideation and behaviors and depression when compared to prevalent metformin users. There was no significant difference in the risk of anxiety between the two groups.The results of this study suggest that children and adolescents using GLP-1 RA for obesity or YT2D were at lower risk of suicidal ideation and behaviors, and depression compared to prevalent metformin users. The risk of anxiety remained non-significant, but the higher trend warrants future surveillance by pediatricians, psychologists, and pharmacoepidemiologists. Question: Findings: Meaning:
GLP-1 Therapies